
Supply chain issues concerning Novo Nordisk’s fast-acting insulin product Novorapid (insulin aspart) have been resolved, industry media Dagens Pharma reports.
Logistical challenges involved in transporting the drug from the US had meant that Novo Nordisk has struggled to supply vials of the injectable treatment since early May, a problem that also affected parallel importers Paranova, 2care4, and Orifarm.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app